1. CureDuchenne Responds to FDA Advisory Committee’s Recommendation Against Approval of Eteplirsen for Duchenne Muscular Dystrophy

    Posted on April 26, 201612:21 am

      CureDuchenne, the California-based nonprofit organization dedicated to finding a cure for every person with Duchenne muscular dystrophy, has released the following statement from its co-founder and CEO, Debra Miller, following the recommendation against approval by the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) for Sarepta’s Read more »

  2. Sarepta Advisory Committee Meeting

    Posted on April 22, 201611:45 pm

      As I prepare to travel to Monday’s Advisory Committee meeting I continue to be disappointed by the FDA Peripheral and Central Nervous System Drugs Advisory Committee’s initial review of Sarepta’s Duchenne muscular dystrophy drug eteplirsen. Despite this news we need to remember The FDA’s initial reaction is just that – an initial response – Read more »

  3. Supporting Sarepta, Providing Hope

    Posted on April 19, 20163:11 pm

      For those who battle against Duchenne muscular dystrophy, there is more hope now than ever. Recent medical breakthroughs in the form of effective drugs are slowing the disease’s progression and giving patients, families and supporters belief in a positive future. Hope is more than a feeling, and here at CureDuchenne we take that belief Read more »